Zymeworks (ZYME) Other Working Capital Changes (2023 - 2026)
Zymeworks (ZYME) posted Other Working Capital Changes of -$340000.0 for Q1 2026, up 56.35% sequentially from -$779000.0 in Q4 2025, and up 83.76% YoY from -$185028.6 in Q1 2025.
Analysis
Zymeworks (ZYME) Other Working Capital Changes (2023 - 2026) Analysis & Trends
Zymeworks has reported Other Working Capital Changes for 4 years, with the latest figure at -$340000.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 83.76% year-over-year to -$340000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.4 million (down 1344.45% YoY) and the FY2025 annual result came in at -$23.2 million, down 751.76% from the prior year.
- Other Working Capital Changes improved to -$340000.0 in Q1 2026 per ZYME's latest filing, from -$779000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $10.0 million in Q4 2024 and troughed at -$18.0 million in Q3 2023.
- A 5-year average of -$544529.4 and a median of -$648000.0 in 2022 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2024 and 2025: Other Working Capital Changes soared 121.76% in 2024, then tumbled 1046.35% in 2025.
- Over 4 years, Other Working Capital Changes stood at $3.6 million in 2023, then plunged by 144.34% to -$1.6 million in 2024, then jumped by 51.28% to -$779000.0 in 2025, then jumped by 56.35% to -$340000.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$340000.0, -$779000.0, and -$614000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Zymeworks | 2.15 Bn | 1.88 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -248,000.00 |
| Jun 30, 2026 | -248,000.00 |
| Mar 31, 2026 | -340,000.00 |
| Mar 31, 2026 | -340,000.00 |
| Dec 31, 2025 | -779,000.00 |
| Dec 31, 2025 | -779,000.00 |
| Sep 30, 2025 | -614,000.00 |
| Sep 30, 2025 | -614,000.00 |
| Jun 30, 2025 | -19.68 Mn |
| Jun 30, 2025 | -19.68 Mn |
| Mar 31, 2025 | -2.09 Mn |
| Mar 31, 2025 | -2.09 Mn |
| Dec 31, 2024 | -1.60 Mn |
| Dec 31, 2024 | -1.60 Mn |
| Sep 30, 2024 | 3.33 Mn |
| Sep 30, 2024 | 3.33 Mn |
| Jun 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 2.08 Mn |
| Mar 31, 2024 | -259,000.00 |
| Mar 31, 2024 | -259,000.00 |